1. 2018
  2. Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?

    Venken, K., Favreau, M., Gaublomme, D., Menu, E., Vanderkerken, K. & Elewaut, D., Sep 2018, In : Molecular Immunology. 101, p. 521-526 6 p.

    Research output: Contribution to journalArticle

  3. 2017
  4. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma

    Favreau, M., Menu, E., Gaublomme, D., Vanderkerken, K., Faict, S., Maes, K., De Bruyne, E., Govindarajan, S., Drennan, M., Van Calenbergh, S., Leleu, X., Zabeau, L., Tavernier, J., Venken, K. & Elewaut, D., Dec 2017, In : Leukemia. 31, 12, p. 2678-2685 8 p.

    Research output: Contribution to journalArticle

  5. Both mucosal- associated invariant and natural killer T cell deficiency in multiple myeloma can be countered by PD-1 inhibition

    Favreau, M., Venken, K., Faict, S., Maes, K., De Veirman, K., De Bruyne, E., Leleu, X., Boon, L., Elewaut, D., Vanderkerken, K. & Menu, E., 26 Jun 2017, In : Haematologica. 102, 7, p. e266-e270 5 p.

    Research output: Contribution to journalLetter

  6. Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells

    De Beule, N., Menu, E., Bertrand, M. J., Favreau, M., De Bruyne, E., Maes, K., De Veirman, K., Radwanska, M., Samali, A., Magez, S., Vanderkerken, K. & De Trez, C., Mar 2017, In : Oncotarget. 241, 4, p. 534-546 12 p., 4860.

    Research output: Contribution to journalArticle

  7. Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition

    Favreau, M., Venken, K., Faict, S., Maes, K., De Veirman, K., De Bruyne, E., Leleu, X., Elewaut, D., Vanderkerken, K. & Menu, E., 2017, In : Belgian Journal of Hematology. 102, 7, p. 16-16 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

  8. 2016
  9. The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma

    Favreau, M., Menu, E., Vanderkerken, K., Faict, S., Maes, K., Van Valckenborgh, E., De Bruyne, E., Govindarajan, S., Drennan, M., Leleu, X., Zabeau, L., Tavernier, J., Venken, K. & Elewaut, D., 1 Dec 2016, In : Blood. 128, 22 2075, p. 2075 1 p., vol. 128 no. 22 2075.

    Research output: Contribution to journalMeeting abstract (Journal)

  10. Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

    Favreau, M., Vanderkerken, K., Elewaut, D., Venken, K. & Menu, E., 26 Apr 2016, In : Oncotarget. 7, 17, p. 23128-40 13 p.

    Research output: Contribution to journalArticle

  11. The immunosuppressive role of the adipokine leptin in multiple myeloma

    Favreau, M., Venken, K., De Bruyne, E., Van Valckenborgh, E., Maes, K., Vanderkerken, K., Elewaut, D. & Menu, E., 2016, In : Belgian Journal of Hematology. p. 17-17 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

Previous 1 2 Next

ID: 181629